Deal-Making
thumbnail
Deal MakingAstellas’ Xyphos, Kelonia ink $800m cancer-focused partnershipAstellas’ Xyphos, Kelonia ink $800m cancer-focused partnership
Astellas subsidiary Xyphos and Kelonia Therapeutics have signed a research and licensing deal worth $800 million to develop immuno-oncological therapies.